The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer

The GIRAFE phase II trial on MVCT-based “volumes of the day” and “dose of the day” addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer

During exclusive curative radiotherapy for head and neck tumors, the patient’s organs at risk (OAR) and target volumes frequently change size and shape, leading to a risk of higher toxicity and lower control than expected on planned dosimetry. Adaptive radiotherapy is often necessary but 1) tools ar...

Full description

Bibliographic Details
Main Authors: Vincent Esteyrie, Baptiste Gleyzolle, Amélie Lusque, Pierre Graff, Anouchka Modesto, Michel Rives, Michel Lapeyre, Jacques Desrousseaux, Eliane Graulières, Gregory Hangard, François-Xavier Arnaud, Regis Ferrand, Jean-Pierre Delord, Muriel Poublanc, Muriel Mounier, Thomas Filleron, Anne Laprie
Format: Article
Language:English
Published: Elsevier 2019-05-01
Series:Clinical and Translational Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630818301265

Internet

http://www.sciencedirect.com/science/article/pii/S2405630818301265

Similar Items